Integrative Landscape of Dry AMD Pathogenesis, Models, and Emerging Therapeutic Strategies

Area of Science:

• Ophthalmology
• Molecular Biology
• Genetics

Background:

• Dry age-related macular degeneration (AMD) is the primary cause of irreversible vision loss in older adults, with limited effective treatments.
• Unlike exudative AMD, dry AMD progresses slowly, leading to geographic atrophy (GA) and significant central vision impairment.
• Current FDA-approved treatments offer modest benefits, necessitating further research into underlying mechanisms and novel therapeutic strategies.

Purpose of the Study:

• To provide a comprehensive overview of the molecular and cellular mechanisms driving dry AMD progression.
• To summarize key pathogenic pathways, including oxidative stress, lipid dysregulation, complement activation, and lipofuscin accumulation.
• To review current and emerging therapeutic strategies and discuss future research directions for dry AMD.

Main Methods:

• Literature review synthesizing current research on dry AMD pathogenesis.
• Analysis of molecular and cellular mechanisms implicated in dry AMD.
• Summary of mechanistic mouse models used to study dry AMD.
• Evaluation of current and emerging therapeutic interventions.

Main Results:

• Key pathogenic pathways identified include oxidative stress, lipid dysregulation, complement activation, mitochondrial dysfunction, and RPE lipofuscin accumulation.
• Mechanistic mouse models aid in understanding disease progression and evaluating therapeutic targets.
• Emerging therapies include complement inhibitors, visual cycle modulators, and mitochondrial-protective agents.

Conclusions:

• A deeper understanding of dry AMD's complex mechanisms is crucial for developing effective treatments.
• Mechanistic insights and disease models are vital for advancing translational research.
• Future therapeutic development should focus on targeted, stage-specific interventions for dry AMD.